Translational Awards
Translational Awards support research teams developing cardiovascular medicines and technologies through early-phase trials, advancing solutions to unmet clinical needs towards patient benefit and commercialisation.
Browse similar grants
Funder: British Heart Foundation
Due Dates: February 3, 2027 (Preliminary application) | August 4, 2027 (Preliminary application) | By invitation (Full application)
Funding Amounts: No funding ceiling; justified project costs for up to 3 years
Summary: Supports early-stage cardiovascular medicines and technologies from initial development through phase II trials towards patient benefit and commercialisation.
Key Information: Applications must be completed in partnership with the host institution’s Technology Transfer Office.
Description
The British Heart Foundation’s Translational Awards advance novel cardiovascular medicines and technologies along the pathway from fundamental discovery to human studies, patient benefit and commercialisation. Projects may begin and end anywhere from initial development through pre-clinical studies to early-phase clinical trials, up to and including phase II. The endpoint must represent a significant scientific or value inflection point.
Supported approaches include small-molecule and biological therapeutics, drug repurposing, devices, surgical techniques, diagnostics, imaging, digital solutions, cell therapy and regenerative medicine, and early-phase studies evaluating efficacy and safety. The scheme prioritises inventive solutions to unmet needs in heart and circulatory diseases, supported by proof-of-concept data, a strong intellectual property position and a development proposition capable of attracting follow-on investment.
